Development and progress of Ireland's biobank network: Ethical, legal, and social implications (ELSI), Standardized documentation, sample and data release, and international perspective
MetadataShow full item record
Biobank Ireland Trust (BIT) was established in 2004 to promote and develop an Irish biobank network to benefit patients, researchers, industry, and the economy. The network commenced in 2008 with two hospital biobanks and currently consists of biobanks in the four main cancer hospitals in Ireland. The St. James's Hospital (SJH) Biobank coordinates the network. Procedures, based on ISBER and NCI guidelines, are standardized across the network. Policies and documents - Patient Consent Policy, Patient Information Sheet, Biobank Consent Form, Sample and Data Access Policy (SAP), and Sample Application Form have been agreed upon (after robust discussion) for use in each hospital. An optimum sequence for document preparation and submission for review is outlined. Once consensus is reached among the participating biobanks, the SJH biobank liaises with the Research and Ethics Committees, the Office of the Data Protection Commissioner, The National Cancer Registry (NCR), patient advocate groups, researchers, and other stakeholders. The NCR provides de-identified data from its database for researchers via unique biobank codes. ELSI issues discussed include the introduction of prospective consent across the network and the return of significant research results to patients. Only 4 of 363 patients opted to be re-contacted and re-consented on each occasion that their samples are included in a new project. It was decided, after multidisciplinary discussion, that results will not be returned to patients. The SAP is modeled on those of several international networks. Biobank Ireland is affiliated with international biobanking groups - Marble Arch International Working Group, ISBER, and ESBB. The Irish government continues to deliberate on how to fund and implement biobanking nationally. Meanwhile BIT uses every opportunity to promote awareness of the benefits of biobanking in events and in the media. Copyright © 2013, Mary Ann Liebert, Inc. 2013.
Showing items related by title, author, creator and subject.
Meir, K.; Gaffney, E.; Simeon-Dubach, D.; Ravid, R.; Watson, P.; Schacter, B.; Morente, M.; Bjugn, R.; Clark, B.; De Blasio, P.; Carpenter, J.; Deschenes, M.; Devereux, L.; Dhir, R.; Goebell, P.; Grizzle, W.; Hainaut, P.; Mes-Masson, A.; Miranda, L.; Parry-Jones, A.; Riegman, P.; Casali-Da-Rocha, J.; Soares, F.; Vaught, J.; Zeps, Nikolajs (2011)The biobanking literature frequently addresses donor and societal issues surrounding biobanking, but the biobanker's perspective is rarely highlighted. While not comprehensive, this article offers an overview of the human ...
Patients' experiences on donation of their residual biological samples and the impact of these experiences on the type of consent given for the future research use of the tissue: A systematic reviewWai, C.; Mackey, S.; Hegney, Desley (2012)Aim: This review aimed to critically appraise, synthesise and present the best available evidence related to the experiences of patients who have donated their residual biological samples and the impact of this experience ...
Lochmüller, H.; TorrentFarnell, J.; Le Cam, Y.; Jonker, A.; Lau, L.; Baynam, G.; Kaufmann, P.; Dawkins, Hugh; Lasko, P.; Austin, C.; Boycott, K. (2017)© 2017 European Society of Human Genetics. The International Rare Diseases Research Consortium (IRDiRC) has agreed on IRDiRC Policies and Guidelines, following extensive deliberations and discussions in 2012 and 2013, as ...